key: cord-0929172-v3ypgsuj
authors: Wang, Li; Kainulainen, Markus H.; Jiang, Nannan; Di, Han; Bonenfant, Gaston; Mills, Lisa; Currier, Michael; Shrivastava-Ranjan, Punya; Calderon, Brenda M.; Sheth, Mili; Mann, Brian R.; Hossain, Jaber; Lin, Xudong; Lester, Sandra; Pusch, Elizabeth; Jones, Joyce; Cui, Dan; Chatterjee, Payel; Jenks, Harley M.; Morantz, Esther; Larson, Gloria; Hatta, Masato; Harcourt, Jennifer; Tamin, Azaibi; Li, Yan; Tao, Ying; Zhao, Kun; Lacek, Kristine; Burroughs, Ashely; Wong, Terianne; Tong, Suxiang; Barnes, John R.; Tenforde, Mark W.; Self, Wesley H.; Shapiro, Nathan I.; Exline, Matthew C.; Files, D. Clark; Gibbs, Kevin W.; Hager, David N.; Patel, Manish; Laufer Halpin, Alison S.; McMullan, Laura K.; Lee, Justin S.; Xie, Xuping; Shi, Pei-Yong; Davis, C. Todd; Spiropoulou, Christina F.; Thornburg, Natalie J.; Oberste, M. Steven; Dugan, Vivien; Wentworth, David E.; Zhou, Bin
title: Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
date: 2022-01-05
journal: bioRxiv
DOI: 10.1101/2021.11.24.469906
sha: 4bad975d49e35882be0adfc93b32bd9a9774ac16
doc_id: 929172
cord_uid: v3ypgsuj

The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of many new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccines. To ascertain and rank the risk of VOCs and VOIs, we analyzed their ability to escape from vaccine-induced antibodies. The variants showed differential reductions in neutralization and replication titers by post-vaccination sera. Although the Omicron variant showed the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retained moderate neutralizing activity against that variant. Therefore, vaccination remains the most effective strategy to combat the COVID-19 pandemic.

The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in 36 the emergence of many new variant lineages that have exacerbated the COVID-19 pandemic. 37

Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or 38 international authorities based on many factors including their potential impact on vaccines. To 39 ascertain and rank the risk of VOCs and VOIs, we analyzed their ability to escape from vaccine-40 induced antibodies. The variants showed differential reductions in neutralization and replication 41 titers by post-vaccination sera. Although the Omicron variant showed the most escape from 42 neutralization, sera collected after a third dose of vaccine (booster sera) retained moderate 43 neutralizing activity against that variant. Therefore, vaccination remains the most effective 44 strategy to combat the COVID-19 pandemic. Currently circulating variants are acquiring additional substitutions/deletions, which may further 137 affect transmission, disease severity, or vaccine effectiveness and require prompt evaluation. 138

Utilizing the short turnaround time of reverse genetics, we generated additional Alpha and Beta 139 reporter viruses to examine the effects of specific substitutions that occurred in nature (Fig. 2c) . 140

While the 3 deletions and 7 substitutions in the Alpha variant spike protein (Extended Data Table  141 1) had a very small impact (1.3-fold) on neutralizing activity of vaccinee sera, we found the 142 addition of the single E484K substitution in spike reduced the neutralizing titer of the Alpha variant 143 by an additional 1.6-fold (2.1-fold compared to the 614D) (Fig. 2c) . The importance of spike-144 E484K is further demonstrated in a Beta reporter virus that encoded the spike-484 reversion 145 (B.1.351+K484E), which was found to be 3-fold more susceptible to neutralization compared to 146 an unmodified Beta variant B.1.351 (2.0-fold vs 6.1-fold) (Fig. 2c) . Interestingly, the N501Y 147 substitution had little impact on the neutralization of the Beta variants (5.6-fold vs. 6.1-fold). A which reduced the neutralizing titers by 2.6-fold, compared to the 614D virus (Fig. 2c) . 155

Considering the plasticity of the SARS-CoV-2 spike to substitutions and deletions, as well as the 156 recombination-prone nature of coronaviruses, substitutions and deletions present in current 157 variants may also occur in future variants in different combinations or in different genetic 158 backgrounds. Therefore, it is important to use reverse genetics or other focused approaches to 159 assess the impact and understand the functionality of specific mutations in naturally occurring 160

To better understand the effect of variant spikes on viral fitness in the presence and absence of 163 neutralizing antibodies, we compared the replication of reporter viruses with the variant spikes in 164

Calu-3 cells, which are a human lung epithelial cell line (Fig. 2d) . In the absence of inhibitory sera, 165

while Delta replicated to significantly higher titer than the original S-614D reference virus, its 166 infectious titer was comparable to the S-614G virus and many other variants. Interestingly, in the 167 presence of sera, even highly diluted, the titers of 614D and 614G viruses were reduced by more (FRNT50 = 5). As anticipated from neutralization escape data (Fig. 2a) , the Beta and Omicron 170 variants replicated efficiently in the presence of both concentrations of sera (Fig. 2d) . Intriguingly, 171 the Delta variant also replicated efficiently and only had a 3-fold reduction in titer at 5x sera 172 concentration (Fig. 2d) . The Delta variant's ability to replicate efficiently in the presence of sub-173 neutralizing concentrations of antisera may have facilitated infections of people with low-to-174 modest levels of neutralizing antibodies induced by prior infection or vaccination. The immune 175 evasion of Delta variant may be an additive or synergistic result of spike mutations that reduce 176 neutralizing activity and fitness advantages (e.g., better S1/S2 cleavage and cell entry) that are 177 unrelated to neutralization but enhance replication and transmission. 178

Notably, all post-second-dose sera tested neutralized these variants with FRNT50 titers higher 180 than 10 and most of them higher than 40, except against the Omicron variant, which had 181 neutralizing titers between 5 and 40 ( Fig. 2 and Supplementary Table 1 ). It has been widely 182 accepted in the influenza vaccine field that a neutralizing titer (hemagglutination inhibition titer) of 183 40 or higher is deemed protective (>50% reduction of infection rate) 12 and a 8-fold reductions in 184 neutralization in vitro is a consideration for updating the influenza vaccine strain. For COVID-19 185 vaccines, few studies on correlates of protection have been published but suggest a titer of 50-186 100 is the minimum protective neutralizing titer 13,14 and the fold reduction warranting a vaccine 187

change have yet to be determined. This is also complicated by the unknown role of other effectors 188 in vaccine protection such as memory B-cell or T cell immunity 15 . However, the level of 189 neutralizing antibody titer is apparently predictive of the level of immune protection [16] [17] [18] [19] . As Table 1 ). This encoding an aspartate (D) or glycine (G) at position 614 were assigned respective "614D" and 250 "614G" labels. Variants that did not satisfy the above criteria were consolidated into "Other 251 Lineage(s)." Clinical statistics included all daily cases and deaths reported to the CDC 252 surveillance network with marked consent. Applied data analytics excluded non-contracted US 253 and global surveillance statistics to limit the impact of non-standardized reporting methodologies 254 and regional over-sampling bias within our dataset. 255 256

Risk-benefit analysis. A comprehensive risk-benefit analysis was conducted for using 258 recombinant SARS-CoV-2 reporter viruses in neutralization assays. Briefly, the benefits of using 259 the reporter viruses are: 1) enabling rapid characterization of variants before they are detected in 260 the United States or before CDC receives specimens; 2) eliminating all fixation and staining steps 261 following the same design as reported previously 24 . The spike gene of this progenitor reporter 303 virus was excised by AscI and BamHI-HF restriction enzymes, resulting in a linearized vector into which synthetic variant spike genes can be assembled using Gibson Assembly (NEB). The 305

Gibson Assembly reaction was then transformed into TransforMax™ EPI300™ Electrocompetent 306 E. coli (Lucigen). Transformations were immediately recovered in SOC medium at 30°C for 1 307 hour, and plated on LB agar plates containing 25 µg/ml chloramphenicol, followed by 308 approximately 2 days of incubation at 30°C. Colonies were picked and inoculated into LB broth 309 containing 25 µg/ml chloramphenicol for approximately 16±2 hours followed by induction for 310 approximately 4±1 hours at 30°C. DNA was extracted and the sequence was verified by Illumina 311 next-generation sequencing (NGS). 

Each dot represents the neutralizing titer (FRNT 50 ) of an individual serum sample; at least 20 postsecond-dose sera were tested against each variant. The average fold changes relative to reference virus 614D (set as 1-fold) are shown on the top of the graph. For each variant, the average fold change is the geometric mean of the individual FRNT 50 ratios (614D/variant) calculated for each serum sample. Dashed line represents the limit of quantitation (LOQ). (a) All WHO and US-SIG designated SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) were tested using reporter viruses. The geometric mean FRNT 50 titers are shown on the graph with standard deviation. 

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission 465 in vivo

Spike mutation D614G alters SARS-CoV-2 fitness

SARS-CoV-2 spike D614G change enhances replication and transmission

Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01, 471 technical briefing 3. London, United Kingdom: Public Health England

SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for 476 global discourse

Emergence of SARS-CoV-2 B.1.1.7 Lineage -United States

Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States

Detection of a SARS-CoV-2 variant of concern in South Africa

Spatiotemporal pattern of COVID-19 spread in Brazil

COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic 488 lineages and P.1 emergence

SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second 491 Wave of COVID-19 in Maharashtra

Immunogenicity and protective efficacy of influenza 494 vaccination

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 496 infection

Correlates of protection against SARS-CoV-2 in rhesus macaques

Adaptive immunity to SARS-CoV-2 and COVID-19

Neutralising antibody titres as predictors of protection against SARS-CoV-2 502 variants and the impact of boosting: a meta-analysis

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 505 in nonhuman primates

Evidence for antibody as a protective correlate for COVID-19 vaccines